New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDulaglutide vs Pentapeptide-18

Dulaglutide vs Pentapeptide-18

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Dulaglutide
Skin & CosmeticAnti-Aging & Longevity
Pentapeptide-18
Summary
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide that mimics the sequence of enkephalin, an endogenous neuropeptide. It acts on neuronal pain receptors in facial muscles to reduce muscle contraction intensity and depth of expression lines, functioning similarly to Argireline (Acetyl Hexapeptide-3) but via a different receptor mechanism.
Half-Life
~5 days
Not applicable (topical)
Admin Route
SubQ
Topical
Research
Typical Dose
0.75 mg → 1.5 mg
0.005–0.05% in formulation
Frequency
Once weekly
Twice daily
Key Benefits
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
  • Reduces depth of expression lines (forehead, crow's feet, glabellar)
  • Inhibits acetylcholine release for muscle-relaxing effect
  • Complementary mechanism to Argireline for enhanced anti-wrinkle activity
  • Reversible and well-tolerated
  • No risk of systemic paralysis at cosmetic concentrations
  • Suitable for daily use in serums and creams
Side Effects
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
  • Generally very well-tolerated topically
  • Rare skin sensitivity or mild irritation
  • Theoretical opioid receptor desensitization with very prolonged high-dose use (not documented cosmetically)
Stacks With